<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157687</url>
  </required_header>
  <id_info>
    <org_study_id>MicrobiomStudy</org_study_id>
    <nct_id>NCT03157687</nct_id>
  </id_info>
  <brief_title>Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation</brief_title>
  <official_title>Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation Under Mixed Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study should reveal differences in composition of luminal and mucosa-associated&#xD;
      microbiome of the human gastrointestinal tract.Therefore bacterial species of different&#xD;
      intestinal location sites (small intestine and colon) isolated of biopsies were compared to&#xD;
      bacterial composition of stool samples. Additionally the bacterial composition of healthy&#xD;
      persons, patients with inflammatory bowel disease and with liver disease (liver cirrhosis)&#xD;
      will be compared to detect influence of local and systemic inflammation on microbiome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dysbiosis of human gut microbiome is discussed in the pathogenesis of many disorders, also&#xD;
      including gastrointestinal (e.g. inflammatory bowel disease, IBD) or liver diseases (e.g.&#xD;
      liver cirrhosis) . A detailed analysis of intestinal bacterial patterns might reveal&#xD;
      important findings for understanding disease pathogenesis. Thereby many studies only analysed&#xD;
      the luminal microbiome of stool samples, whereas mucosa-associated bacteria have possibly a&#xD;
      greater impact on human health and immune system .&#xD;
&#xD;
      To determine the differences of luminal and mucosa-associated bacteria, stool and mucosa&#xD;
      samples (via biopsies) will be collected. Thereby biopsies are taken of different intestinal&#xD;
      locations (small intestine and colon) to detect variations along intestinal tract. An&#xD;
      additional comparison of bacterial patterns in patients with chronic, local (IBD) and&#xD;
      systemic inflammation (with liver cirrhosis) or without intestinal inflammations (healthy&#xD;
      controls) should reveal the influence of microbiome on or by inflammation processes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bacterial composition</measure>
    <time_frame>1 day</time_frame>
    <description>detection of bacterial families in stool and mucosa samples</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Human Microbiome</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Blood sampling for nutrition and inflammatory status&#xD;
Stool sampling before preventive gastroscopy and colonoscopy&#xD;
Questionnaires about general health, gastrointestinal symptoms and 3-day food record&#xD;
Collection of biopsies in duodenum during gastroscopy&#xD;
Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inflammatory bowel disease (IBD)</arm_group_label>
    <description>Blood sampling for nutrition and inflammatory status&#xD;
Stool sampling before indicated gastroscopy and colonoscopy&#xD;
Questionnaires about general health, gastrointestinal symptoms and 3-day food record&#xD;
Collection of biopsies in duodenum during gastroscopy&#xD;
Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver transplantation recipient (LTX)</arm_group_label>
    <description>Blood sampling for nutrition and inflammatory status&#xD;
Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)&#xD;
Questionnaires about general health, gastrointestinal symptoms and 3-day food record&#xD;
Collection of biopsies in duodenum during gastroscopy&#xD;
Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        healthy controls patients with inflammatory bowel disease patients with liver disease&#xD;
        (liver cirrhoses) and indication for LTX-evaluation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy volunteers with indication for cancer screening without gastrointestinal&#xD;
             symptoms&#xD;
&#xD;
          -  patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)&#xD;
&#xD;
          -  patients with indication for evaluation of liver transplantation (LTX)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other gastrointestinal disease, e.g. celiac disease, gastrointestinal tumors&#xD;
&#xD;
          -  antibiotic treatment within 6 weeks before gastroscopy / colonoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yurdaguel Zopf, Prof. Dr.</last_name>
    <email>yurdaguel.zopf@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walburga Dieterich</last_name>
    <email>walburga.dieterich@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yurdaguel Zopf</last_name>
      <email>yurdaguel.zopf@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

